

V. 研究成果の刊行物・別刷

Review Article**Hypersensitive bladder: A solution to confused terminology and ignorance concerning interstitial cystitis**

Yukio Homma

Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan

Abbreviations & Acronyms

BPS = bladder pain syndrome
IC = interstitial cystitis
ICS = International Continence Society
HSB = hypersensitive bladder
OAB = overactive bladder
PBS = painful bladder syndrome

Correspondence: Yukio Homma M.D., Ph.D., Department of Urology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-8655, Japan. Email: homma-uro@umin.ac.jp

Received 9 August 2013;
accepted 4 September 2013.

Abstract: Taxonomy or nomenclature concerning interstitial cystitis and its related symptom syndromes is in a state of confusion. After analyzing the reasons for confusion in regard to three components (disease name, symptoms, Hunner's lesion), I would like to propose a new term, "hypersensitive bladder", taking after overactive bladder, as a solution. Hypersensitive bladder symptoms are defined as "increased bladder sensation, usually associated with urinary frequency and nocturia, with or without bladder pain." The proposal of hypersensitive bladder is based on: (i) it does not appear a symptom syndrome, but a disease by ending with an organ name, "bladder"; (ii) it does not contain confusable symptom terms (pain and urgency), but indicates irritative symptoms including pain and urgency; and (iii) it suggests pathophysiological hyperactivity of sensory nerves. Interstitial cystitis is defined by three requirements: (i) hypersensitive bladder symptoms; (ii) bladder pathology; and (iii) no other diseases, where bladder pathology should be clearly stated either as Hunner's lesion or glomerulations after hydrodistention. Hypersensitive bladder can be used for the condition with hypersensitive bladder symptoms, but no obvious disease explaining hypersensitive bladder symptoms identified. Interstitial cystitis is a representative disease causing hypersensitive bladder symptoms, most typically with pain, but might be painless and indistinguishable from overactive bladder. Introducing hypersensitive bladder as a counter concept of overactive bladder into bladder dysfunction taxonomy will facilitate clinical practice and research progress, and attract considerable attention from the medical world.

Key words: hypersensitivity, interstitial cystitis, pain, urgency, urinary bladder.

Introduction

Taxonomy or nomenclature concerning IC and its related symptom syndromes is in a state of confusion.¹ Ambiguous definitions and inaccurate use of terminology generate confusion in practice and research, hindering the progress of research and/or leading to ignorance of IC by the medical world. In this presentation, I analyze the backgrounds and reasons for the confusion in regard to three components (disease name, symptoms, Hunner's lesion), and would like to suggest a solution.

Disease name

In the literature, we encounter IC, PBS, BPS, and chimeric terms combining IC and syndromes (IC/PBS and IC/BPS or PBS/IC and BPS/IC). Chronic pelvic pain syndrome is also used as an umbrella term including IC, as patients with IC often perceive pain in the lower abdomen or external genitalia.

PBS is defined by the ICS as "suprapubic pain related to bladder filling, accompanied by other symptoms such as increased daytime and night-time frequency, in the absence of proven urinary infection or other obvious pathology".² According to ICS, "PBS is a preferable term to IC", and "IC is a specific diagnosis and requires confirmation by typical cystoscopic and histological features", although typical cystoscopic and histological features are not clearly mentioned. Definitions by The Panel of the American Urological Association Guideline and by the Society for Urodynamics and Female Urology are identical: "an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than 6 weeks' duration, in the absence of infection or other identifiable causes."³ BPS is defined by the European Society for the Study of Interstitial Cystitis as "chronic pelvic pain, pressure, or discomfort perceived to be related to the urinary bladder accompanied by at least one other urinary symptom such as persistent urge to void or urinary frequency. Confusable diseases as the cause of symptoms must be excluded."⁴

The definitions of these symptom syndromes all share two requirements: unpleasant symptoms and lack of identifiable diseases explaining those symptoms. In other words, the symptom syndromes do not imply symptoms alone or a specific disease. They are a tentative naming for convenience to describe a condition accompanying obvious symptoms without identifiable diseases. Chimeric terms combining IC and syndromes, IC/PBS or IC/BPS, are even more complicated; they would indicate conditions presenting the symptoms in the absence of obvious diseases with possible presence of IC.⁵ However, these terms are not used distinctly, but rather, interchangeably.

User-friendly and clearly understandable terminology is required for efficient and accurate communications.

Symptoms

PBS and BPS contain the words “painful” and “pain”, which leads to a misunderstanding that the patients have to complain of pain. In reality, a proportion of patients do not.^{6,7} Complaints heard might not be directly linked to pain; that is, the incessant need to void because of discomfort, loss of normal urinary sensation and an irritable sensation with only a little urine in the bladder. These unpleasant or discomfort sensations might be a kind of pain by scientific definition; pain is defined as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage.”⁸ However, it is unrealistic for common physicians and patients to use “pain” to describe pressure or discomfort in their own words. Pain is commonly understood as “the feeling you have when part of your body hurts” or “highly unpleasant physical sensation caused by illness or injury”. The criteria for clinical trials of IC by the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases require symptoms of “either pain associated with bladder OR urinary urgency.”⁹ In other words, National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases criteria, which are allegedly too restrictive for clinical diagnosis, do not require pain as the symptom. Mentioned in the proposal paper for BPS is that “many patients report a sensation of pressure or discomfort in the bladder/pelvic area and do not report this sensation as pain but rather as urgency.”¹⁴

The discrepancy between the academic definition of pain and common usage of this word can lead to confusion. It might result in untoward consequences to patients’ benefit by excluding painless patients from the scope of PBS or BPS. It might create a belief that there is injury in the bladder. Furthermore, pain might be too strong a word both for patients and physicians. As far as the syndromes contain “pain”, patients are never free of a fear of experiencing pain. Physicians might prefer to steer clear of the case, taking the approach that pain is the toughest symptom to control and should be managed by a pain specialist.

Urgency is another symptom issue. It is the key symptom of OAB, and defined as “sudden compelling desire to void, which is difficult to defer.”²² Urgency is also regarded as one of the key symptoms associated with IC or IC-like conditions,^{9,10} and urgency in this case might not be identical to OAB urgency. Urgency in OAB is characterized by sudden onset and/or fear of

leakage, whereas urgency in IC is of a persistent nature, and is associated with the fear of pain.¹¹ However, a distinction between these two urgencies on the basis of symptoms is not simple; approximately 40% of women with OAB also reported urgency as a result of pain, pressure or discomfort, and 60% of women with IC indicated that the urgency occurred suddenly rather than gradually.¹² Anyway, we still have to use the same word, “urgency”, even though urgency is different in OAB and IC. This is an inevitable confusion. The ICS definition in 2002, which restricted urgency to the sudden strong desire to void (and excluded the non-sudden strong desire to void from urgency), is a source of confusion. The original urgency (1988 definition) allowed for two types of strong desire to void. Amending the definition of urgency to the original one to encompass the sensation of IC-related urgency is a straightforward solution, yet it might stir up even more confusion.

Taken together, a word different from pain or urgency might be preferable for describing symptoms of IC.

Hunner’s lesion

It has been postulated that IC can be categorized into two types, one with Hunner’s lesion and one without. The former is known as classic type, ulcer type or ulcerative IC, although Hunner’s lesion is not an “ulcer” in pathological meaning. Endoscopically, it is recognized as a well-demarcated reddish mucosal lesion lacking in the normal capillary structure. Classic IC is characterized by older age, being more symptomatic and more inflammatory reactions. By contrast, those without Hunner’s lesion reported more often extra-bladder symptoms and other functional syndromes, such as irritable bowel syndrome, fibromyalgia or chronic fatigue syndrome.^{13–15} Extra-bladder symptoms might be secondary to bladder symptoms or of a primary nature, with the bladder being an innocent bystander.¹⁶ Alternatively, there might be a common pathological pathway for bladder and extra-bladder symptoms.¹⁷

These two types of IC show marked histopathological differences; denudation of epithelium and inflammatory reactions are evident only in IC with Hunner’s lesion.¹⁸ Recent studies further underscore inflammatory reactions in patients with classic IC; high levels of intravesical nitric oxide,¹⁹ elevated pro-inflammatory gene expression in the bladder biopsy^{20,21} or in urinary sediment.^{22,23} Pronociceptive inflammatory reactions mediating TRP channels and/or ASIC channel are found to be upregulated.²⁴ Clinically, this rationalizes the use of corticosteroid or surgery to resect the inflamed tissue of the classic IC bladder.^{25,26}

It is conceivable that Hunner’s lesion, an obvious inflammatory lesion, causes pain or other symptoms. Why do patients without Hunner’s lesion show such symptoms? Recent basic research has revealed that the urothelium is not a simple barrier to urine, but rather with sensory nerve properties.²⁷ The sensory nerve has a double function: an afferent function informing the central nervous system of physical or chemical stimuli; and an efferent function releasing mediators, such as substance P, calcitonin gene-related peptide and tachykinins, in response to sensory activity. The latter function triggers smooth muscle contraction, immune cell migration and mast cell degranulation. Thus, overactivity of sensory nerves induces chronic

inflammatory reactions, which might result in hypersensitivity of C-fiber nociceptors, forming a vicious cycle leading to allodynia or hyperalgesia of the bladder.^{28,29} Central pain amplification might exaggerate hypersensitivity to visceral stimuli.³⁰ For example, sciatic nerve injury, an insult outside the bladder, can cause bladder hypersensitivity by upregulation of chemokine signaling in the bladder sensory neurons.³¹ Upregulation of NGF expression in IC patients without Hunner's lesion suggests sensory overactivity in this specific type of IC.^{24,32}

Despite such a pronounced symptomatic, histological and pathophysiological distinction, it is not common practice to carry out cystoscopy to detect Hunner's lesion. In addition, Hunner's lesion is easily overlooked without intentional search. Surprisingly, many clinical studies lack information on the presence or absence of Hunner's lesion for the study population. Clinical practice and research combining these two into a single group of a vaguely-defined word (PBS, BPS, PSB/IC or BPS/IC) lead to further confusion in diagnosis, management and investigation of IC.

Historical considerations

IC was originally described as a distinct bladder disease with "ulcerative" lesion on cystoscopy.³³ However, bladder pathology is not always identifiable in patients with symptoms suggestive of IC.³⁴ A substantial portion of patients suspected as having IC had no evidence of bladder pathology, yet complained of debilitating symptoms including pain. Regarding the necessity for a diagnostic name for such patients, two approaches could be feasible. One is expanding the scope of IC; those complaining of IC-like symptoms with no obvious other diseases are included in IC irrespective of the presence or absence of bladder pathology or without exploration of bladder pathology. The other approach is using a symptom syndrome as a proxy for a disease name, such as PBS. As the expanded IC and symptom-based diagnosis (i.e. PBS) refer to a similar condition, these two terms were naturally combined (i.e. IC/PBS). Thus IC, PBS, IC/PBS or whatever like these, all terms were used interchangeably to indicate the IC-like condition ranging from the bladder with definite Hunner's lesion to a persistent complaint of unpleasant bladder sensation resistant to antibiotics. To create order in the midst of this confusion, BPS has been introduced, with IC abolished from medical terminology.⁴ In reality, however, BPS is regarded as an alternative to PBS, and a chimeric word such as BPS/IC is still alive. Hence, IC or IC-like patients are left mixed up or unclassified, showing diversity in symptoms (with or without pain), cystoscopic findings (with or without Hunner's lesion) and histology (with or without inflammation).³⁵

Origin of confusion

Why such a confusion? I believe it is because we have adopted symptom syndromes to describe this condition. Symptom syndromes refer to a set of symptoms without identifiable diseases. They do not imply symptoms alone or a specific disease. They do not define the extent of clinical tests to find the identifiable disease. It is a tentative naming for the sake of convenience with vague definition, which allows arbitrary interpretations by




Fig. 1 Distinction between symptom, symptom syndrome and disease. A cohort of symptomatic patients might present with symptoms such as pain and discomfort (symptom). If they have no obvious diseases, they are called by a symptom syndrome for convenience, such as PBS (syndrome). When detailed examinations have shown bladder pathology, the condition should be called by a disease name, such as IC (disease). In reality, these three are used interchangeably, causing confusion among patients, physicians and researchers.

users. PBS, BPS, PBS/IC, PB/IC, and IC are used without strict discrimination for the difference among syndrome, symptom and disease (Fig. 1). The most well-known symptom syndrome of lower urinary tract dysfunction could be OAB. Its definition is, "urinary urgency, usually associated with urinary frequency, with or without urgency incontinence."²² Although originally developed as a symptom syndrome, it is actually functioning as a disease. The abbreviation is not OABS (overactive bladder syndrome), but simply OAB. It ends with an organ name, bladder, sounding as if it referred to a disease of the urinary bladder associated with bladder overactivity. OAB is a successful naming in that it has been accepted widely, leading to public awareness of urinary problems in general and input from pharmaceutical companies to develop new medicines for lower urinary tract symptoms. We should take advantage of the popularity and naming of OAB in resolving confusion surrounding IC and its related symptom syndromes.

Hypersensitive bladder as an proposal

Under these considerations, I would like to propose a new term "hypersensitive bladder" (HSB).³⁶ HSB was once used as a term for idiopathic sensory urgency and "early" IC.³⁷ Some editorials or papers used sensory disorder or hypersensitivity to describe the pathophysiology of IC.^{38,39}

The proposal of HSB is based on: (i) it does not appear a symptom syndrome, but a disease ending with "bladder"; (ii) it does not contain pain or urgency, but indicates irritative symptoms including pain and urgency; and (iii) it suggests pathophysiological hyperactivity of sensory nerves. HSB symptoms are defined as "increased bladder sensation, usually associated with urinary frequency and nocturia, with or without bladder pain." It looks like OAB symptoms: urinary urgency, usually associated with urinary frequency and nocturia, with or without urgency incontinence.




Fig. 2 Relationship between HSB and its related terms. Symptoms of OAB (urinary urgency, usually associated with urinary frequency and nocturia, with or without urgency incontinence) and HSB (increased bladder sensation, usually associated with urinary frequency and nocturia, with or without bladder pain) are overlapping, although OAB with leakage and HSB with pain are readily separated. Symptoms of IC usually present HSB symptoms, often accompanying pain, but occasionally mimicking OAB symptoms.




Fig. 3 Algorithm for hypersensitive bladder symptoms. HSB symptoms should be investigated for the causes. When there is no obvious disease, the condition is called as HSB. When bladder pathology is identified in HSB, the diagnosis of IC is made. When there is no such bladder abnormality, the condition remains as HSB. The presence or absence of Hunner lesion should be recorded for IC cases.

In contrast, IC should be defined by three conditions: HSB symptoms, bladder pathology, and no other diseases explaining the symptoms. Bladder pathology shows Hunner's lesion or glomerulations after hydrodistention, if following NIDDK criteria.⁹ However, the specificity of glomerulations is challenged and needs further investigation. Tentatively, by allowing both findings for bladder pathology, we should describe the presence or absence of Hunner's lesion for each patient for the future analysis.

HSB can be used as a diagnostic name for the condition that is suspected of IC, but has not fulfilled the requirements for IC diagnosis. HSB symptoms might occur with or without evidence for bladder pathology. It could accompany chronic pelvic pain or functional disorders. By analogy, OAB can be used as a diagnostic name for the condition that is suspected of detrusor overactivity, but has not fulfilled the requirements for DO diagnosis. OAB symptoms might occur with or without evidence for detrusor overactivity. It could accompany benign prostatic enlargement or stress urinary incontinence.

The relationship between HSB and related terms, IC and OAB, is shown in Fig. 2. Symptomatically, HSB and OAB are substantially overlapping. Detailed voiding recording with reference to bladder sensation indicated increased urinary sensation at a given bladder volume in OAB.^{40,41} Urodynamically, those diagnosed as OAB have shown more detrusor overactivity and lower bladder volume at urinary sensation and increased sensitivity to electrostimulation.⁴² These observations suggest OAB symptoms also reflect hypersensitivity of the bladder. IC is a representative disease causing HSB symptoms, most typically with pain, but might be painless and indistinguishable from OAB.

An algorithm for hypersensitive bladder symptoms is shown in Fig. 3. When there is no obvious disease explaining HSB symptoms, the condition is called HSB. When bladder pathology is identified in HSB, the diagnosis of IC is made. When there is no such bladder abnormality, the condition remains as HSB. Bladder pathology is either Hunner's lesion or glomerulations after hydrodistention, although the latter is to be

challenged for specificity. The presence or absence of Hunner's lesion should be recorded to characterize IC cases.

With these definitions, the following makes sense: (i) a woman complaining of HSB symptoms proved to have carcinoma *in situ* of the bladder; (ii) a woman with HSB symptoms was diagnosed with HSB because no obvious diseases were apparent, but now she is diagnosed with IC based on cystoscopic abnormality; and (iii) a man with HSB showed no abnormal findings at hydrodistention, so he remained as HSB.

Introducing HSB, the counter concept of OAB, into bladder dysfunction taxonomy will clarify current confusion surrounding IC, and importantly lessen the ignorance of IC by the medical society.

Conflict of interest

None declared.

References

- Homma Y. Lower urinary tract symptomatology: its definition and confusion. *Int. J. Urol.* 2008; **15**: 35–43.
- Abrams P, Cardozo L, Fall M *et al.* The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. *Neurourol. Urodyn.* 2002; **21**: 167–78.
- Hanno P, Dmochowski R. Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. *Neurourol. Urodyn.* 2009; **28**: 274–86.
- van de Merwe JP, Nordling J, Bouchelouche P *et al.* Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. *Eur. Urol.* 2008; **53**: 60–7.
- Warren JW, Meyer WA, Greenberg P *et al.* Using the International Continence Society's definition of painful bladder syndrome. *Urology* 2006; **67**: 1138–42. discussion 1142–1133.
- Irwin P, Samsudin A. Reinvestigation of patients with a diagnosis of interstitial cystitis: common things are sometimes common. *J. Urol.* 2005; **174**: 584–7. discussion 587.
- Ito T, Ueda T, Homma Y *et al.* Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: analysis of 282 Japanese patients. *Int. J. Urol.* 2007; **14**: 1068–70.
- Merskey H. The taxonomy of pain. *Med. Clin. North Am.* 2007; **91**: 13–20. vii.
- Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. *J. Urol.* 1988; **140**: 203–6.
- O'Leary MP, Sant GR, Fowler FJ Jr *et al.* The interstitial cystitis symptom index and problem index. *Urology* 1997; **49**: 58–63.
- Diggs C, Meyer WA, Langenberg P *et al.* Assessing urgency in interstitial cystitis/painful bladder syndrome. *Urology* 2007; **69**: 210–4.
- Clemens JQ, Bogart LM, Liu K *et al.* Perceptions of "urgency" in women with interstitial cystitis/bladder pain syndrome or overactive bladder. *Neurourol. Urodyn.* 2011; **30**: 402–5.
- Erickson DR, Morgan KC, Ordille S *et al.* Nonbladder related symptoms in patients with interstitial cystitis. *J. Urol.* 2001; **166**: 557–61. discussion 561–552.
- Nickel JC, Tripp DA, Pontari M *et al.* Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. *J. Urol.* 2010; **184**: 1358–63.
- Peters KM, Killinger KA, Mounayer MH *et al.* Are ulcerative and nonulcerative interstitial cystitis/painful bladder syndrome 2 distinct diseases? A study of coexisting conditions. *Urology* 2011; **78**: 301–8.
- Peters KM. Interstitial cystitis—is it time to look beyond the bladder? *J. Urol.* 2012; **187**: 381–2.
- Warren JW, Wesselmann U, Morozov V *et al.* Numbers and types of nonbladder syndromes as risk factors for interstitial cystitis/painful bladder syndrome. *Urology* 2011; **77**: 313–9.
- Fall M, Johansson SL, Aldenberg F. Chronic interstitial cystitis: a heterogeneous syndrome. *J. Urol.* 1987; **137**: 35–8.
- Logadottir YR, Ehren I, Fall M *et al.* Intravesical nitric oxide production discriminates between classic and nonulcer interstitial cystitis. *J. Urol.* 2004; **171**: 1148–50. discussion 1150–1141.
- Gamper M, Viereck V, Geissbuhler V *et al.* Gene expression profile of bladder tissue of patients with ulcerative interstitial cystitis. *BMC Genomics* 2009; **10**: 199.
- Ogawa T, Homma T, Igawa Y *et al.* CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. *J. Urol.* 2010; **183**: 1206–12.
- Tyagi P, Killinger K, Tyagi V *et al.* Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. *J. Urol.* 2012; **187**: 2243–8.
- Blalock EM, Korret GS, Stromberg AJ *et al.* Gene expression analysis of urine sediment: evaluation for potential noninvasive markers of interstitial cystitis/bladder pain syndrome. *J. Urol.* 2012; **187**: 725–32.
- Homma Y, Nomiya A, Tagaya M *et al.* Increased mRNA expression of genes involved in nociceptive inflammatory reactions in bladder tissue of interstitial cystitis. *J. Urol.* 2013; **190**: 1925–31.
- Soucy F, Gregoire M. Efficacy of prednisone for severe refractory ulcerative interstitial cystitis. *J. Urol.* 2005; **173**: 841–3. discussion 843.
- Rossberger J, Fall M, Jonsson O *et al.* Long-term results of reconstructive surgery in patients with bladder pain syndrome/interstitial cystitis: subtyping is imperative. *Urology* 2007; **70**: 638–42.
- Birder LA, de Groat WC. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. *Nat. Clin. Pract. Urol.* 2007; **4**: 46–54.
- Geppetti P, Nassini R, Materazzi S *et al.* The concept of neurogenic inflammation. *BJU Int.* 2008; **101** (Suppl 3): 2–6.
- Sculptoreanu A, de Groat WC, Buffington CA *et al.* Abnormal excitability in capsaicin-responsive DRG neurons from cats with feline interstitial cystitis. *Exp. Neurol.* 2005; **193**: 437–43.
- Twiss C, Kilpatrick L, Craske M *et al.* Increased startle responses in interstitial cystitis: evidence for central hyperresponsiveness to visceral related threat. *J. Urol.* 2009; **181**: 2127–33.
- Foster R, Jung J, Farooq A *et al.* Sciatic nerve injury induces functional pro-nociceptive chemokine receptors in bladder-associated primary afferent neurons in the rat. *Neuroscience* 2011; **183**: 230–7.
- Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. *Urology* 2007; **70**: 463–8.
- Hunner G. A rare type of bladder ulcer in women: report of cases. *Boston Med. Surg. J.* 1915; **172**: 660–64.
- Parsons JK, Parsons CL. The historical origins of interstitial cystitis. *J. Urol.* 2004; **171**: 20–2.
- Teichman JM, Parsons CL. Contemporary clinical presentation of interstitial cystitis. *Urology* 2007; **69**: 41–7.
- Homma Y. Hypersensitive bladder: towards clear taxonomy surrounding interstitial cystitis. *Int. J. Urol.* 2013; **20**: 742–3.
- Frazer MI, Haylen BT, Sissons M. Do women with idiopathic sensory urgency have early interstitial cystitis? *Br. J. Urol.* 1990; **66**: 274–8.
- Erickson DR. Identifying biomarkers for interstitial cystitis/bladder pain syndrome. *J. Urol.* 2012; **187**: 1958–9.
- Lazzeri M, Montorsi F. The therapeutic challenge of "chronic cystitis": search well, work together, and gain results. *Eur. Urol.* 2011; **60**: 78–80.
- Yamaguchi O, Honda K, Nomiya M *et al.* Defining overactive bladder as hypersensitivity. *Neurourol. Urodyn.* 2007; **26**: 904–7.
- Fujihara A, Ukimura O, Honjo H *et al.* Urge perception index of bladder hypersensitivity. *J. Urol.* 2013; **189**: 1797–803.
- Lee SR, Kim HJ, Kim A *et al.* Overactive bladder is not only overactive but also hypersensitive. *Urology* 2010; **75**: 1053–9.

Effects of L-Arginine, Mirabegron, and Oxybutynin on the Primary Bladder Afferent Nerve Activities Synchronized With Reflexic, Rhythmic Bladder Contractions in the Rat

Naoki Aizawa,¹ Yukio Homma,² and Yasuhiko Igawa^{1*}

¹Department of Continence Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

²Department of Urology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

Aims: We measured single-unit mechanosensitive afferent activities (SAAs) during reflexic, rhythmic bladder contractions (RBCs), and examined whether L-arginine, an NO substrate, and mirabegron, a β_3 -adrenoceptor agonist, and oxybutynin, an antimuscarinic agent, can affect the SAAs in such condition. **Methods:** Twenty-nine female Sprague-Dawley rats were anesthetized. SAA was identified by electro-stimulation of the left pelvic nerve and by bladder distension, and was divided into A δ - or C-fibers by conduction velocity. To produce the RBCs, right L6 dorsal roots were kept intact. Under an isovolumetric condition, vehicle and L-arginine (300 mg/kg) or mirabegron (1 mg/kg) or oxybutynin (1 mg/kg) were administered intravenously. **Results:** All of the A δ - (n = 26) and C-fibers (n = 29) capable of responding to bladder distention were also responsive to bladder contractions during RBCs. The amplitude and duration of RBCs significantly decreased after mirabegron- and oxybutynin-administrations, but not after L-arginine-administration. The interval of RBC was significantly elongated after L-arginine- and mirabegron-administrations. Regarding the SAAs, the peaks of firing rate (FR) during RBCs and FR during the non-contractile phase were decreased after L-arginine-administration, which were more remarkable for A δ -fibers than C-fibers. Similar results were observed after mirabegron-administration only for A δ -fibers. After oxybutynin-administration, the peak of FR of both fiber-SAAs significantly decreased, but the change was not significant when the value was normalized by the amplitude of RBCs. **Conclusions:** The present results indicate that mechanosensitive A δ - and C-fibers were also responsive to bladder contractions, and that NO production and β_3 -adrenoceptor stimulation can inhibit SAAs mainly of A δ -fibers synchronized with RBCs. *NeuroUrol. Urodynam.* © 2014 Wiley Periodicals, Inc.

Key words: afferent; β_3 -adrenoceptor; nitric oxide; Sprague-Dawley rats; urinary bladder

INTRODUCTION

Reflexic bladder contractions begin when the afferent impulses conveyed by the pelvic afferent nerves reach the complex neural interactions of the central nervous system (CNS: pons, periaqueductal grey (PAG), brain frontal cortex, lumbosacral spinal cord).¹ Thus, excitation of the mechanoreceptors in sensory nerve endings plays an important role in triggering the micturition reflex. The afferent innervation of the urinary bladder consists primarily of small myelinated A δ -fiber and unmyelinated C-fiber axons that respond to mechanical stimuli. In the pelvic nerve of cats, various authors^{2,3} have described that mechanosensitive fibers (conduction velocities: CV = 1.7–2.5 m/sec) in the detrusor muscle layer, which may include A δ -fibers, can be responded to distension but also to contractions of the bladder, suggesting that contractions and distension of the bladder activate the afferent endings by a common mechanism.

In the rat, there is evidence that many C-fibers (CV = less than around 2.0 m/sec) respond to slow distension of the bladder with physiological volumes: some of them are "volume" receptors that do not respond to contractions of the bladder.^{4,5} Chuang et al. reported that in the rat, volume receptors are activated by bladder distension but do not fire in response to bladder contractions, whereas tension receptors located in the muscle layers deeper in the bladder wall respond to an isovolumetric bladder contraction as well as distension,⁶ which is also observed similarly in the cat.

We have previously demonstrated that the increased endogenous nitric oxide (NO) and stimulation of β_3 -adrenoceptor (β_3 -AR) can inhibit single-unit afferent activities (SAAs)

of mechanosensitive primary bladder afferent nerves during bladder distension in an in vivo rat model.^{7–9} In that model, no reflexic bladder contractions are elicited by bladder distension, as bilateral L6 dorsal roots, the main afferent pathway from the bladder, have been dissected off. In the current study, in order to investigate the characteristics of SAAs capable of responding to bladder contractions, we developed a new model for measurement of SAAs synchronized with reflexic, rhythmic bladder contractions (RBCs), in which keeping the right L6 dorsal root intact although the left L6 dorsal root is resected for the afferent measurements, by modifying our previous SAAs-measurement model. By using this new model, we investigated whether an increase in endogenous NO production induced by L-arginine (an NO-substrate), mirabegron (a β_3 -AR agonist), and oxybutynin (an antimuscarinic agent), can affect the SAAs during reflexic RBCs.

Karl-Erik Andersson led the peer-review process as the Associate Editor responsible for the paper.

Conflict of interest: This study was supported by the research grant from Astellas Pharma Inc. (Tokyo, Japan).

Grant sponsor: Grant-in-Aid for Scientific Research (YI and NA); Grant numbers: 40159588; 80595257; Grant sponsor: Astellas Pharma Inc. (Tokyo, Japan)

*Correspondence to: Yasuhiko Igawa, M.D., Ph.D., Professor and Chairman Department of Continence Medicine, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

E-mail: yigawa-jua@umin.ac.jp

Received 31 October 2013; Accepted 20 January 2014

Published online in Wiley Online Library

(wileyonlinelibrary.com).

DOI 10.1002/nuu.22571

MATERIALS AND METHODS

Animals

Thirty-eight adult female Sprague-Dawley rats weighing 185–242 g (9–11 weeks old) were used (Nihon SLC, Shizuoka, Japan). The rats were maintained under standard laboratory conditions with a 12:12 hr light: dark cycle, and free access to food pellets and tap water. The protocol was approved by the Animal Ethics Committee of The University of Tokyo Graduate School of Medicine and in line with NIH guidelines for the care and use of experimental animals.

Surgical Procedure for the SAAs Measurements

The rats were anesthetized with urethane (1.2 g/kg intraperitoneally). Body temperature was maintained by a heated blanket at 38°C. The left pelvic nerve was dissected from surrounding tissue proximal to the major pelvic ganglion. A pair of silver electrodes was placed around the pelvic nerve. A polyethylene catheter (Clay-Adams PE-50, Becton Dickinson and company, Parsippany, NJ) was inserted in the bladder through the dome. Fine filaments were dissected from the left L6 dorsal root and placed across shielded bipolar silver electrodes. Clearly different unitary action potentials of afferent fiber originating from the bladder were identified by electrical stimulation of the pelvic nerve and bladder distention with saline. These action potentials were discriminated by the Spike2 (CED, Cambridge, UK) impulse shape recognition program. CV was calculated from the latency of response to electrical stimulation and the conduction distance between stimulation and recording sites, which was based on our anatomical data. Fibers were grouped based on CV. Those with a CV < 2.5 m/sec were considered to correspond to unmyelinated C-fibers and those with CV ≥ 2.5 m/sec to myelinated Aδ-fibers.¹⁰ After detecting and classifying these mechanosensitive afferent activities, the following experiment was performed.

Experimental Protocol of the SAAs Synchronized With RBCs

To produce the RBCs, right L6 dorsal roots were kept intact and the urethral meatus was clamped at the level of the urethral meatus by forceps. After the bladder had been emptied, saline was instilled into the bladder at a rate of 0.16 ml/min. Bladder pressure and SAAs were recorded continuously on the Spike2 program. When RBCs appeared, the instillation was stopped and the bladder was kept under an isovolumetric condition. After RBCs appeared reproducibly for a period of 5 min, vehicle was administered, and then L-arginine (300 mg/kg) or mirabegron (1 mg/kg) or oxybutynin (1 mg/kg) was administered. The parameters of the bladder pressure and SAAs were analyzed during three or four of RBCs before and after the vehicle- and drug-administrations.

Following cystometric and SAA parameters were analyzed and represented as numeric-values or % of baseline (before administration) values: amplitude (cmH₂O) and duration (sec) of contraction; interval between contractions (sec); bladder basal pressure (cmH₂O); time to first peak (TFP) and time to first response (TFR) of contraction after vehicle- or drug-administrations (sec); mean firing rate (FR) during non-contraction phase (Hz); peak FR of SAA activity (Hz) and FR/bladder pressure (Hz/cmH₂O) during contraction, which value of FR/bladder pressure was used for normalization with change in amplitude of RBCs.

Drugs

N,N-Dimethylacetamide (DMA), L-arginine, and oxybutynin were purchased from Sigma-Aldrich (St. Louis, MO). Cremophor was purchased from Nacalai Tesque, Inc. (Kyoto, Japan). Mirabegron, (*R*)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl] acetanilide, was provided from Astellas Pharma Inc. (Tokyo, Japan). L-arginine and oxybutynin were dissolved in saline. Mirabegron was dissolved in 5% DMA and 5% cremophor, and 90% distilled water. Drugs and vehicle were administered intravenously through a polyethylene catheter (PE-50) placed in the right external jugular vein.

Statistical Analysis

All data are expressed as mean ± standard error of mean (S.E. M.). Results for two group comparisons were analyzed using paired Student's *t*-test. Results for multiple comparisons were analyzed using two-way ANOVA followed by Tukey's test. *P*-values < 0.05 are considered statistically significant.

RESULTS

Characteristics of SAAs Synchronized With RBCs

Totally 50 rats were subjected to induction of stable RBCs under an isovolumetric condition, but 12 animals (approximately 24%) failed to show stable RBCs, and these animals were excluded. Finally 38 rats (approximately 76%) were used for the present study, and average volume of saline instilled intravesically for inducing stable RBCs were 0.67 ± 0.04 ml (range: 0.31–1.23 ml). Bladder distension induced RBCs. We sometimes faced difficulty to keep an ideal isovolumetric condition for eliciting RBCs continuously. Thus we needed to do experiments within a short term period when RBCs were evoked continuously, which allowed us to evaluate three or four RBCs after vehicle- or drug-administrations. The shape of these RBCs was apparently different from that of "microcontractions" defined in our previous study⁷ (Fig. 1). For example, the amplitude of the RBCs ranged 12–54 cmH₂O, and the corresponding value of microcontractions was 1.5–7 cmH₂O and was of myogenic origin as no reflex arc through the L6 dorsal roots was preserved.⁷

All of the both Aδ- and C-fibers that had responded to bladder distention were also responsive to bladder contractions during RBCs (Aδ-fibers: *n* = 33, CV: 8.14 ± 0.81 m/sec; C-fibers: *n* = 35, CV: 1.87 ± 0.41 m/sec).

At the beginning of the study for the drug-administrations, saline was administered repeatedly to investigate the time-dependent influence on the bladder pressure parameters and SAAs of both fibers (Aδ- and C-fibers) throughout the experiments. As a result, none of the bladder pressure parameters (*n* = 9) and SAAs (Aδ-fibers: *n* = 7, C-fibers: *n* = 6) investigated changed significantly (data shown as the supplemental files).

Effects of L-Arginine, Mirabegron, and Oxybutynin on Bladder Pressure

The amplitude and duration of RBCs did not change either after vehicle- or L-arginine-administration. On the other hand, interval of RBCs, TFR, and TFP were significantly elongated after L-arginine-administration, although the basal pressure was decreased by vehicle-administration alone (Figs. Fig. 1A and 2A–D; and Table I). After mirabegron-administration, the amplitude and duration of RBCs significantly decreased




Fig. 1. Representative recordings of bladder pressure (upper tracings) and firing rate (lower tracings) during RBCs before and after vehicle- and drug-administrations. Moreover, several parameters were indicated in tracing A. A: Changes in the bladder pressure and firing rate of C-fiber with vehicle- and L-arginine-administrations. B: Changes in the bladder pressure and firing rate of Aδ-fiber with vehicle- and mirabegron-administrations. C: Changes in the bladder pressure and firing rate of C-fiber with vehicle- and oxybutynin-administrations.

(Figs. Fig. 1B and 2E, F). Similar effects were observed also after oxybutynin-administration (Figs. Fig. 1C and 2I, J). An elongation in RBCs-interval and a decrease in basal pressure were observed after mirabegron-administration but not oxybutynin-administration (Fig. 2G, H and K, L). There were no significant differences in TFR and TFP after either mirabegron- or oxybutynin-administration (Figs. 1 and 2; and Table I).

Effects of L-Arginine, Mirabegron, and Oxybutynin on SAAs Activities

After L-arginine-administration, the peak FR of SAAs and FR/bladder pressure values during RBCs and FR during the non-contraction phase were decreased, which were more remarkable in Aδ-fibers than C-fibers (Figs. Fig. 1A, 3A-C, and 4A-C). Similar results in Aδ-fibers, but not in C-fibers, were observed after

TABLE I. Numeric-Values of "TFR" and "TFP" After Vehicle- or Drug-Administrations

	Parameters (sec)	Vehicle-administration	Drug-administration	Numbers
L-arginine (300 mg/kg)	Time to first response (TFR)	82.67 ± 12.71	684.89 ± 148.54 ^a	n = 9
	Time to first peak (TFP)	91.44 ± 13.35	725.44 ± 137.79 ^a	
Mirabegron (1 mg/kg)	Time to first response (TFR)	68.77 ± 9.42	74.00 ± 15.29	n = 13
	Time to first peak (TFP)	80.54 ± 9.91	81.69 ± 15.52	
Oxybutynin (1 mg/kg)	Time to first response (TFR)	94.43 ± 17.43	66.43 ± 11.83	n = 14
	Time to first peak (TFP)	107.71 ± 17.69	76.14 ± 12.20	

The values are indicated as mean ± S.E.M.

^aP < 0.01 significant difference from vehicle-administration (paired Student's t-test).




Fig. 2. Bladder pressure parameters before and after vehicle- and drug-administrations. A–D: L-arginine-administration. E–H: Mirabegron-administration. I–L: Oxybutynin-administration. White bars indicate the numeric-values (correspond to left Y-axis), and gray bars indicate the relative % values (correspond to right Y-axis).

mirabegron-administration (Figs. 1B, 3D–F, and 4D–F). After oxybutynin-administration, the peak FR of both fiber-SAAs significantly decreased, but the change was not significant when the value was normalized by the amplitude of RBCs (i.e., FR/bladder pressure during contraction) (Figs. 1C, 3G–I, and 4G–I).

DISCUSSION

In the present study, we have confirmed that all of the both A δ - and C-fibers capable of responding to bladder distention (so-called mechanosensitive afferent fibers) were also responsive to bladder contractions during RBCs in the rat. In the present-experimental set-up, we have resected unilateral (left) L6 dorsal root for SAAs-measurement and preserved only the contralateral (right) L6 dorsal root, which may make RBCs under an isovolumetric bladder condition relatively weak and difficult to maintain continuously compared with the previous studies,^{11–13} in which the micturition reflex arc has been fully preserved. Nevertheless in the present study, we could measure the SAAs during RBCs induced by bladder distension, which seems more physiological condition rather than RBCs induced by artificial procedure such as using drugs or electrical stimulation of the nerves. A previous study in the rat reported that tension receptors located in the deeper muscle layers

of the bladder wall respond to isovolumetric bladder contractions as well as distension,⁶ and A δ -fibers are known to be located primarily within the detrusor smooth muscle layer.^{14–17} The present findings obtained in A δ -fibers, which showed that this class of fibers responded to bladder contractions but also to bladder distention, are in line with those previous findings.

In the present study, we have also confirmed that C-fibers capable of responding to bladder distention are also responsive to RBCs. In contrast, previous reports demonstrated that many afferents of C-fibers respond to slow distension of the bladder with physiological volumes: some of these are “volume” receptors that do not respond to contractions.^{4–6} However, these previous studies did not investigate the direct SAAs of mechanosensitive C-fibers during the reflexic bladder contractions in an isovolumetric condition. Moreover, Shea et al. reported that there are many types of afferent fibers including A δ - and C-fibers so-called mechano- or chemo-sensor individually and each fiber possibly has both characters, and that it was difficult to divide between A δ - and C-fibers functionally, except CV values, in the rat.⁵ Thus, it seems reasonable that C-fibers respond to not only bladder distention but also bladder contractions potentially in the present study. Taken together, the present study demonstrated that mechanosensitive afferent activities of both A δ - and C-fibers of the rat urinary bladder




Fig. 3. Responses of afferent activities of A δ -fibers to vehicle and drug-administrations. A–C: l-arginine-administration. D–F: Mirabegron-administration. G–I: Oxybutynin-administration. White bars indicate the numeric-values (correspond to left Y-axis), and gray bars indicate the relative % values (correspond to right Y-axis).

are capable of being responsive to both stretch and contractile stimuli.

We have investigated the effects of three drugs on RBCs and SAAs in this situation. After l-arginine-administration, the amplitude and duration of RBCs did not change whereas RBCs disappeared for a while as reflected the elongated TFR and TFP, and the elongated interval of RBCs. These results suggest that l-arginine can inhibit the afferent pathway from the bladder, but not the efferent pathway. This observation is consistent with the previous finding that intraurethral administration of NO donor (S-Nitroso-N-acetyl-DL-penicillamine and nitroprusside) significantly decreased the bladder contraction frequency without any changes of bladder contraction amplitude.¹¹ The finding that the peak of FR during RBCs after l-arginine-administration significantly decreased without any changes of bladder pressure itself may support l-arginine's selective action on the afferent pathway. Moreover, the mean FR during non-contraction phase, which may reflect the SAAs during bladder distention, was decreased after l-arginine-administrations. Our previous study during bladder filling is further supporting these findings in the present study.⁹

On the other hand, after mirabegron- and oxybutynin-administrations, the amplitude and duration of RBCs signifi-

cantly decreased. In addition, the interval of RBCs elongated and the basal pressure decreased significantly, respectively, only after mirabegron-administration but not oxybutynin-administration. These results suggest that mirabegron can inhibit the both afferent and efferent pathways from/to the bladder, whereas oxybutynin inhibit only efferent pathway. Takasu et al.¹² demonstrated that mirabegron (1 mg/kg intravenously) did not significantly alter either the amplitude or frequency of RBCs, which seems partly different from our findings. In the present study, RBCs under an isovolumetric bladder condition were relatively weak and difficult to maintain continuously as described before. Such differences in experimental condition might have affected to the results of mirabegron's effect. Uchida et al. reported that intravenous oxybutynin administration larger than 0.1 mg/kg significantly reduced the amplitude but did not change frequency of RBCs in an anesthetized rat,¹³ which was consistent with the present study. After mirabegron-administration, the peak of FR of SAAs during RBCs significantly decreased in A δ -fibers, but not in C-fibers. In contrast, the peak of FR of both fiber-SAAs significantly decreased after oxybutynin-administration, but the change was not significant when the value was normalized by the amplitude of RBCs as shown in the result of FR/bladder




Fig. 4. Responses of afferent activities of C-fibers to vehicle- and drug-administrations. A–C: L-arginine-administration. D–F: Mirabegron-administration. G–I: Oxybutynin-administration. White bars indicate the numeric-values (correspond to left Y-axis), and gray bars indicate the relative % values (correspond to right Y-axis).

pressure. These results indicate that the decreased peak FR during RBCs after oxybutynin-administration might result from the weakened bladder contractions. Taken together, these results suggest that the stimulation of β_3 -AR by mirabegron can inhibit mechanosensitive primary A δ afferent activities synchronized with RBCs, but these effects were not observed with oxybutynin. Such observations with mirabegron-treatment are consistent with our previous findings on inhibition of mechanosensitive primary A δ -afferent activities during the bladder contractions (microcontractions) of myogenic origin.⁷

It is conceivable that the activation of bladder afferent nerve fibers during RBCs demonstrated in the current study can facilitate bladder contractions during the voiding phase by providing a sensory input that is used as positive feedback to maintain the contraction of the bladder. If so, drugs that can enhance such afferent input to the CNS may be good candidates for the treatment of detrusor underactivity.

CONCLUSIONS

The present results indicate that mechanosensitive afferent activities of both A δ - and C-fibers of the rat urinary bladder are

capable of being responsive to both stretch and contractile stimuli. L-arginine, an NO substrate, inhibit the activation of both A δ - and C-fibers (mainly A δ -fibers) induced by bladder contractions, whereas mirabegron, a β_3 -AR agonist, has an inhibitory effect only on A δ -fibers. On the other hand, oxybutynin, an antimuscarinic agent, may not have such effects. To our knowledge, this study is the first direct demonstration of the inhibitory actions of L-arginine and mirabegron on SAAs during RBCs.

REFERENCES

1. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. *Nat Rev Neurosci* 2008;9:453–66.
2. Habler HJ, Janig W, Koltzenburg M. Myelinated primary afferents of the sacral spinal cord responding to slow filling and distension of the cat urinary bladder. *J Physiol* 1993;463:449–60.
3. Iggo A. Tension receptors in the stomach and the urinary bladder. *J Physiol* 1955;128:593–607.
4. Morrison J, Wen J, Kibble A. Activation of pelvic afferent nerves from the rat bladder during filling. *Scand J Urol Nephrol Suppl* 1999;201:73–5.
5. Shea VK, Cai R, Crepps B, et al. Sensory fibers of the pelvic nerve innervating the Rat's urinary bladder. *J Neurophysiol* 2000;84:1924–33.
6. Chuang YC, Fraser MO, Yu Y, et al. Analysis of the afferent limb of the vesicovascular reflex using neurotoxins, resiniferatoxin and capsaicin. *Am J Physiol Regul Integr Comp Physiol* 2001;281:R1302–10.

7. Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel beta3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. *Eur Urol* 2012;62:1165-73.
8. Aizawa N, Igawa Y, Nishizawa O, et al. Effects of CL316,243, a beta 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. *NeuroUrol Urodyn* 2010;29:771-6.
9. Aizawa N, Igawa Y, Nishizawa O, et al. Effects of nitric oxide on the primary bladder afferent activities of the rat with and without intravesical acrolein treatment. *Eur Urol* 2011;59:264-71.
10. Sengupta JN, Gebhart GF. Mechanosensitive properties of pelvic nerve afferent fibers innervating the urinary bladder of the rat. *J Neurophysiol* 1994;72:2420-30.
11. Jung SY, Fraser MO, Ozawa H, et al. Urethral afferent nerve activity affects the micturition reflex; implication for the relationship between stress incontinence and detrusor instability. *J Urol* 1999;162:204-12.
12. Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'--(2-[2-hydroxy-2-phenylethyl]amino)ethyl] acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. *J Pharmacol Exp Ther* 2007;321:642-7.
13. Uchida M, Koganei M, Murata N, et al. Effects of 4-ethylamino-2-butynyl(2-cyclohexyl-2-phenyl)glycolate hydrochloride, a metabolite of oxybutynin, on bladder specimens and rhythmic bladder contraction in rats in comparison with oxybutynin. *J Pharmacol Sci* 2004;94:122-8.
14. de Groat WC. The urothelium in overactive bladder: Passive bystander or active participant? *Urology* 2004;64:7-11.
15. Gabella G, Davis C. Distribution of afferent axons in the bladder of rats. *J Neurocytol* 1998;27:141-55.
16. Ouslander JG. Management of overactive bladder. *N Engl J Med* 2004;350:786-99.
17. Vera PL, Nadelhaft I. Anatomical evidence for two spinal 'afferent-interneuron-efferent' reflex pathways involved in micturition in the rat: A 'pelvic nerve' reflex pathway and a 'sacrolumbar intersegmental' reflex pathway. *Brain Res* 2000;883:107-18.

Supporting Information

Additional supporting information may be found in the online version of this article at the publisher's web-site.

Determinants of Nocturia: Pathophysiology and Assessment

Of all lower urinary tract symptoms (LUTS), nocturia is one of the most bothersome complaints of elderly men.¹ Pathophysiology of nocturia conceptually consists of the 3 elements of overproduction of nocturnal urine, small bladder capacity and sleep disorder.^{1,2} These elements are likely to influence or aggravate each other, forming a complicated clinical feature of nocturia.

In this issue of *The Journal* van Doorn et al (page 1034) shed further light on nocturia, using frequency-volume chart variables obtained from 1,142 Dutch men 50 to 78 years old under longitudinal observation lasting 6 years.³ The independent factors identified relative to nocturia were older age, small maximum bladder capacity (less than 300 ml), worse LUTS assessed by I-PSS (International Prostate Symptom Score) exclusive of nocturia score, 24-hour polyuria (greater than 2,800 ml/24 hours) and nocturnal polyuria (proportion of nocturnal voided volume greater than 33% of 24-hour urine volume or nocturnal urine production greater than 90 ml per hour). Comorbidities putative of risk factors such as diabetes and hypertension did not remain as independent factors. Although there are inherent limitations of an observational study, some risk factors for nocturia were identified, which offer speculative pathophysiology of nocturia in men. The authors are to be congratulated for the confirmatory findings of nocturia associated factors in their series of Krimpen longitudinal studies.⁴ Sleep disorder, which was not discussed in this article, is to be investigated in a future study by the authors.

Association of nocturia with I-PSS excluding nocturia score raises the question of what other symptom score is more or less associated with nocturia. Presumably, storage symptoms such as increased micturition frequency, urgency and urgency incontinence are more related to nocturia. However, to determine this relationship, further evaluation using a more detailed and comprehensive symptom assessment is needed. The I-PSS is a questionnaire specific to symptoms of benign prostatic hyperplasia.⁵ Incontinence and pain not addressed by the I-PSS could be related to nocturia,⁶ most probably in those without nocturnal

polyuria. In addition, a longitudinal analysis of the current data set would provide a sequential course of symptom profile in men with nocturia as to what symptom predicts it or what symptom is preceded by it.

In the study by van Doorn et al nocturnal polyuria was expressed in proportion of voided volume at night and nocturnal urine production. Both factors were calculated at bedtime and upon rising in the morning for relative nocturnal polyuria and from 1 to 6 a.m. for absolute nocturnal polyuria under the assumption that urine production is constant between 2 consecutive voids. It is intriguing that these 2 indicators, although intuitively highly correlated, were also independent significant determinants for nocturia. Absolute amount of urine rather than relative ratio of urine excreted at night was more discriminative, since an increase in relative ratio (greater than 33%) was highly prevalent in the elderly population regardless of the presence or absence of nocturia. It is probable that the relative ratio increase occurs earlier and the absolute increase occurs later. The current study could have provided insight into this assumption by sequential analysis and input from vascular and renal physiology.⁷ Alternatively, a higher threshold (ie greater than 50%) may improve the discriminant ability of relative ratio.

Physiologically, the cutoffs for nocturnal factors used by van Doorn et al may not be appropriate. It is regrettable that these factors except relative amount were not adjusted for body size, ie body weight, body height, body mass index or body surface area. Body size is far from constant among races and individuals. The body size of Dutch or European men is not comparable to that of Japanese or Asian men. It is also highly variable within each country and race. Body size and body weight are fundamental clinical and physiological determinants, and the amount of urine excreted or maximum bladder capacity depends on them. Applying these cutoffs to any population or individuals studied may be difficult, although the authors indicate no specific intent of clinical implementation of their results.

Clinical criteria or definition of nocturnal polyuria is debatable. The International Continence Society report states "nocturnal polyuria is present when greater than 20% (young adults) to 33% (over 65 years) (urine) is produced at night."⁸ This definition is ambiguous in terms of age discrimination, and yet it provides the advantage of no need for body size adjustment and is probably most often used as a tentative gold standard. However, in the present study nocturnal urine production of greater than 90 ml per hour is a better alternative than the more discriminative value of greater than 33% and more evidence based.⁹

There are numerous definitions of nocturnal polyuria,^{1,2} some of which are based on body size

adjustment, for example 10 ml/kg body weight per night.¹⁰ Clinical adaptation of a specific cutoff value needs scientific plausibility and generalizability. Also required is practicality, that is, measurement and calculation of urinary volume specifically for nocturnal polyuria should be simple. Pathophysiology of nocturia is complicated by multiple determinants. A common assessment scale for each potential determinant would benefit physicians and patients.

Yukio Homma

*Department of Urology
Graduate School of Medicine
The University of Tokyo
Hongo, Bunkyo-ku, Japan*

REFERENCES

1. Cornu JN, Abrams P, Chapple CR et al: A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management—a systematic review and meta-analysis. *Eur Urol* 2012; **62**: 877.
2. Udo Y, Nakao M, Honjo H et al: Analysis of nocturia with 24-h urine volume, nocturnal urine volume, nocturnal bladder capacity and length of sleep duration: concept for effective treatment modality. *BJU Int* 2011; **107**: 791.
3. van Doorn B, Kok ET, Blanker MH et al: Determinants of nocturia: the Krimpen study. *J Urol* 2014; **191**: 1034.
4. van Doorn B, Blanker MH, Kok ET et al: Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community-based study in older men: the Krimpen study. *Eur Urol* 2013; **63**: 542.
5. Barry MJ, Fowler FJ Jr, O'Leary MP et al: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. *J Urol* 1992; **148**: 1549.
6. Fujimura T, Kume H, Nishimatsu H et al: Assessment of lower urinary tract symptoms in men by International Prostate Symptom Score and core lower urinary tract symptom score. *BJU Int* 2012; **109**: 1512.
7. Agarwal R, Light RP, Bills JE et al: Nocturia, nocturnal activity, and nondipping. *Hypertension* 2009; **54**: 646.
8. Abrams P, Cardozo L, Fall M et al: The standardization of terminology in nocturia: report from the standardization sub-committee of the International Continence Society. *Neurourol Urodyn* 2002; **21**: 179.
9. Blanker MH, Bernsen RM, Bosch LJ et al: Relation between nocturnal voiding frequency and nocturnal urine production in older men: a population-based study. *Urology* 2002; **60**: 612.
10. Homma Y, Yamaguchi O, Kageyama S et al: Nocturia in the adult: classification on the basis of largest voided volume and nocturnal urine production. *J Urol* 2000; **163**: 777.

Influence of Urethane-Anesthesia on the Effect of Resiniferatoxin Treatment on Bladder Function in Rats with Spinal Cord Injury

Naoki Aizawa,¹ Shinichi Ogawa,^{1,2} Rino Sugiyama,^{1,3} Yukio Homma,³ and Yasuhiko Igawa^{1*}

¹Department of Continence Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

²Department of Discovery Research, Mochida Pharmaceutical Co., LTD., Shizuoka, Japan

³Department of Urology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

Aims: We investigated the effect of resiniferatoxin (RTX)-treatment on cystometric parameters in the spinal cord injury (SCI) rats in both conscious and urethane-anesthetized conditions and evaluated the influence of urethane-anesthesia on the effect of RTX on lower urinary tract (LUT) function in SCI rats. **Methods:** Female Sprague-Dawley rats were used. SCI was created by transection of the T8-T9 spinal cord. Four weeks after the transection, the animals were placed in a restraint cage for the first cystometric measurements in a conscious state. Secondary cystometric measurements were performed in a conscious condition following the 1 day after RTX-(0.3 mg/kg) or vehicle-subcutaneous injection. Then the animals were injected with urethane (1.5 g/kg, subcutaneously), and cystometric measurements were repeated four times every 1 hr-interval. **Results:** After the RTX-treatment in a conscious condition, urinary retention was observed in three out of five animals. In addition, the number of non-voiding contractions (NVCs) significantly decreased although their amplitude did not change significantly. After the urethane-injection, all of the animals treated with RTX developed urinary retention. The amplitude of NVCs significantly decreased, whereas the number of NVCs did not change significantly in the RTX-treated group. No cystometric parameters significantly changed after either vehicle- or urethane-injection in the vehicle-treated group. **Conclusions:** The present results indicate that the suppressive effects of RTX on NVCs as well as voiding contractions in SCI rats can be enhanced by urethane-anesthesia. Such suppressive effect of urethane-anesthesia itself should be taken into consideration when we evaluate a drug-effect on LUT function in rats with SCI. *NeuroUrol. Urodynam.* © 2013 Wiley Periodicals, Inc.

Key words: anesthesia; resiniferatoxin; spinal cord injury; Sprague-Dawley rats; urinary bladder

INTRODUCTION

Spinal cord injury (SCI) eliminates voluntary control of micturition and produces an initial period of detrusor areflexia, complete urinary retention that are related to the spinal shock phase. However, micturition reflex reappears at various intervals after injury and mediates automatic micturition and neurogenic detrusor overactivity (DO).¹ It has been reported that transient receptor vanilloid subfamily-1 (TRPV1) is overexpressed in the human urinary bladder following SCI.² For the treatment of lower urinary tract (LUT) dysfunctions induced by SCI, intravesical capsaicin (CAP), or resiniferatoxin (RTX) has been explored to produce clinical benefits for increasing bladder capacity and for decreasing DO as well as voiding bladder contractions. These clinical benefits are presumed to be attributable to desensitization of TRPV1 ion channel.³⁻⁸ Some animal studies^{9,10} demonstrated that systemic treatment with CAP inhibited only the non-voiding contractions (NVCs), of which possibly reflect as DO. In contrast to the clinical observations, these animal studies showed that the voiding bladder contractions were kept in SCI rats under conscious or a low dose of urethane-anesthetized conditions.

Urethane is the most suitable anesthetic for acute and chronic physiological experiments that require demonstration of the micturition reflex.¹¹ On the other hand, urethane potentiated the functions of neuronal nicotinic acetylcholine, γ -aminobutyric acid (GABA)_A, and glycine receptors, and it inhibited N-methyl-D-aspartate (NMDA) and α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in a concentration-dependent manner.^{12,13} Indeed, it has been

reported that the urethane-anesthesia with an usual dose (1.2 g/kg) necessary to anesthetize normal rats markedly suppressed the micturition reflex induced by bladder distension in SCI rats.¹⁰ Thus, it is possible that the urethane can modify the effect of drugs including CAP and RTX in SCI rats. Nevertheless, most of the studies for investigating the effect of drugs on LUT function in rats following SCI have been carried out with urethane-anesthesia.¹⁴⁻¹⁸

The aims of this study were to investigate the effect of RTX-treatment on cystometric parameters in both conscious and urethane-anesthetized conditions in the same SCI rats, and to evaluate the influence of urethane-anesthesia on the effect of RTX in SCI rats.

This study was supported by the research grant from Mochida Pharmaceutical CO., LTD. (Tokyo, Japan).

Lori Birder led the peer-review process as the Associate Editor responsible for the paper.

Grant sponsor: Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sport, Science and Technology of the Japanese Government; Grant numbers: 40159588; 80595257; Grant sponsor: Mochida Pharmaceutical CO., LTD., Tokyo, Japan

*Correspondence to: Yasuhiko Igawa, M.D., Ph.D., Department of Continence Medicine, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan..

E-mail: yigawa-jua@umin.ac.jp

Received 24 September 2013; Accepted 26 November 2013

Published online in Wiley Online Library

(wileyonlinelibrary.com).

DOI 10.1002/nuu.22549

MATERIALS AND METHODS

Animals

Seventeen adult female Sprague-Dawley rats weighing 190–210 g (9–10 weeks-old) were used. The rats were maintained under standard laboratory conditions with a 12:12 hr light:dark cycle, and free access to food pellets and tap water. The protocol was approved by the Animal Ethics Committee of The University of Tokyo Graduate School of Medicine and in line with NIH guidelines for the care and use of experimental animals.

Surgical Procedure for SCI

Spinal transections were performed under isoflurane anesthesia at the level of T8-T9. After the laminectomy, the spinal cord was transected completely using a fine scissors. Gelfoam (Pfizer Japan, Inc., Tokyo, Japan) was placed between the severed ends of the spinal cord. The overlying muscle and skin were closed layer by layer. Each rat was housed in a separate cage. The animals were treated with an antibiotic [Gentamicin sulfate, 0.1 mg/0.1 ml/body, subcutaneously (s.c.)] for 7 days. To prevent over-distension of the bladder, urine was expressed manually every 12 hr until the time when the micturition reflex has been recovered (6–12 days after transection). Four weeks after the transection, following experiments were performed.

Experimental Procedure

A polyethylene catheter (Clay-Adams PE-50, Parsippany, NJ) was implanted into the bladder through the dome for cystometry (CMG) under anesthesia with pentobarbital sodium (35–40 mg/kg, intraperitoneally) (Fig. 1). One day after the catheter-implantation, animals were placed individually into transparent observation chamber. After 10 min adaptation period, base-line (first) eye-wipe test was performed by applying CAP solution (0.05 mg/ml, 20 μ l/eye) on the eye-surface and then counting the number of eye wipes for 1.5 min, which referred to a previous study.¹⁰ The tested eye was rinsed with 0.9% saline and swabbed after CAP application. Then, under isoflurane anesthesia, animals were placed in a restraint cage (Ballman Cage KN-326, Natsume, Tokyo, Japan) and allowed to recover from anesthesia for CMG measurements. The intravesical catheter was connected via a three-way stopcock to a pressure transducers (Nihon Kohden, Tokyo,

Japan) and connected to a syringe pump (KDS 200, Muromachi Kikai Co. Ltd., Tokyo, Japan) for saline instillation at a rate of 12 ml/h. Bladder pressure was measured using data acquisition software (Power Lab, AD Instruments, Sydney, Australia) at a sampling rate of 40 Hz. CMG was repeated four times and the fourth measurement served as the Base1 value in a conscious condition. On the next day, vehicle or RTX (0.3 mg/kg) was injected s. c. under isoflurane anesthesia. One day after the vehicle or RTX injection, secondary eye-wipe test and CMG measurements as the Base2 value in a conscious condition were performed in the same way. After Base2 CMG measurement, the animals were injected with urethane (1.5 g/kg, s. c.), and CMG measurements were repeated four times every 1 hr-interval after the urethane-injection. In the CMG measurements, general cystometric parameters were analyzed. NVCs were determined as the bladder contractions whose amplitude was more than 3 cm H₂O observed for a 3-min period before micturition. In each CMG measurement, the saline-instillation for bladder filling was terminated for 40 min (at 8 ml) or when the leakage of saline through the urethra has been observed.

Drugs

Gentamicin sulfate was purchased from Wako Pure Chemical Industries, Ltd. (Tokyo, Japan). CAP and RTX were purchased from Sigma-Aldrich (St. Louis, MO). Gentamycin was dissolved in saline. CAP and RTX were dissolved in absolute ethanol as a stock solution (0.5 and 3 mg/ml, respectively) and stored at –80°C, and then subsequent dilutions of the drugs were made on the day of the experiment using saline.

Statistical Analysis

All data are expressed as mean \pm SEM. Results for two group comparisons were analyzed using paired Student's *t*-test. Results for multiple comparisons were analyzed using one-way ANOVA followed by Dunnett's test. *P*-values <0.05 are considered statistically significant.

RESULTS

General Characteristics

In the RTX treated group, three animals failed to show sufficient desensitization judged by the eye-wipe test were




Fig. 1. Experimental procedures.

excluded for further investigations. The animals that had too small bladder capacity (<0.6 ml) or no NVCs on the base-line CMG (Base1) were also excluded (N = 4). Finally, 10 SCI animals were used for further investigations (N = 5 in each group, bladder weights of vehicle- and RTX-treated rats: 417 ± 37 and 511 ± 28 mg, respectively, *P* > 0.05).

Eye-Wipe Test and CMG Measurements

In the eye-wipe test, RTX significantly decreased the number of eye wipes, whereas those changes were not observed in vehicle-treated group (Fig. 2A).

After the RTX-treatment in a conscious condition, urinary retention was observed in three out of five animals; the voided volume significantly decreased and the residual volume and the bladder capacity increased (Fig. 2G-I). In addition, the number of NVCs significantly decreased although their amplitude did not change significantly (Fig. 2B,C). On the other hand, no parameters changed significantly after vehicle-treatment (Figs. 2 and 5).

After the urethane-injection, all of the animals treated with RTX developed urinary retention. The amplitude of NVCs significantly decreased, whereas the number of NVCs and other CMG parameters did not change significantly in the RTX-treated group (Figs. 3-5). On the other hand in the vehicle-treated group, no CMG parameters significantly changed after the urethane-injection, with an exception for a single rat developing urinary retention (Figs. 3-5).

DISCUSSION

In the present study, RTX treatment significantly decreased the behavior of eye wipes compared with before-treatment (Base1), whereas such changes were not observed in vehicle-treated group. These results are consistent with the previous findings,^{10,19} and suggest that RTX can cause the desensitization of TRPV1 ion channel.²⁰ On the other hand, three animals failed to make this desensitization sufficiently. We used the dose of 0.3 mg/kg and the period of one day to make desensitization by RTX. This experimental procedure referred




Fig. 2. Results of the eye-wipe test induced by CAP before and after vehicle or RTX treatment (A), and the effects of vehicle or RTX on cystometric parameters in conscious SCI rats (B-I). The values are expressed as mean ± SEM. The values in parenthesis show the number of rats used. **P* < 0.05, ***P* < 0.01, ****P* < 0.001: significant differences from Base1 (paired Student's *t*-test).




Fig. 3. The effects of before and 1–4 hr after urethane-anesthesia on cystometric parameters in vehicle- or RTX-treated SCI rats. The values are expressed as mean \pm SEM. The values in parenthesis show the number of rats used. No significant differences were found in all parameters before and after urethane-anesthesia.




Fig. 4. The effects of before and 1–4 hr after urethane-anesthesia on amplitude (A) and number (B) of NVCs in vehicle- or RTX-treated SCI rats. The values are expressed as mean \pm SEM. The values in parenthesis show the number of rats used. * $P < 0.05$, ** $P < 0.01$: significant differences from Base2 (one-way ANOVA followed by Dunnett's test).

to a previous study,²¹ which demonstrated that the systemic RTX-pretreatment 24 hr before investigation effectively desensitized capsaicin-sensitive bladder afferents. We believe that this experimental procedure was sufficient to make the desensitization by RTX although a few animals failed to induction.

In such condition, conscious CMG measurements revealed that RTX treatment itself developed urinary retention in more than half of rats investigated, which accompanied with the decreased voided volume and the increased residual volume. In addition, the number of NVCs significantly decreased after RTX treatment. These results suggest that the desensitization induced by RTX produce the suppressive effect on the detrusor overactivity as well as micturition reflex, which lead to voiding, in conscious SCI condition. Cheng et al.¹⁰ reported that the NVCs were dramatically attenuated in urethane-anesthetized SCI rat 4 days after treatment of systemic CAP-injection, whereas the voiding contractions were still existed. This previous study was partly inconsistent with our finding, and this discrepancy may be due to the different experimental set-up such as drugs and desensitization period. In the clinical studies, the intravesical CAP and RTX could depress DO as well as voiding contractions although there were controversy of the effects of CAP or RTX on the amplitude of the uninhibited detrusor contractions, in which the amplitude has been shown as the unchanged or the depressed.^{3,4,22,23} Therefore, our finding of the effects of RTX treatment under a conscious condition may be in line with the clinical observations.




Fig. 5. Representative traces of CMG in each group. A: Vehicle-treated group, before and after vehicle and urethane-anesthesia. B: RTX-treated group, before and after RTX and urethane-anesthesia.

Cheng et al. investigated the bladder functions before and at various times after the induction of urethane-anesthesia (1.2 g/kg, s.c.) in CMG measurements. They indicated that the bladder reflex contractions and NVCs in all of the SCI animals ($n=4$) were completely blocked at 3 hr after induction of anesthesia.¹⁰ In addition, they also reported that the injection of urethane-anesthesia at less dose (0.8 g/kg, s.c.) produced the disappearance of the urine voiding in 45% (8/18) in vehicle (for CAP)-treated SCI rats, and the remainder (10/18) of the animals excreted only small amounts of fluid (10% of bladder volume eliminated) during distension of the bladder even though they exhibited large amplitude bladder contractions.⁹ Thus, they concluded that urethane-anesthesia itself markedly suppresses the bladder micturition reflex activities and NVCs. In the present study, we found only one animal which developed urinary retention after urethane-anesthesia in vehicle-treated rats. And, we did not find any cystometric changes, including NVCs and voiding bladder contraction parameters, with higher dose of urethane (1.5 g/kg, s.c.) than the previous studies used. The experimental set-up between these previous findings and our findings were similar, nevertheless, there were large discrepancies of the results between them, and we did not find any exact reasons for these discrepancies.

On the other hand in RTX-treated rats, 1–4 hr after urethane-anesthesia, all of the animals developed urinary retention. In addition, the amplitude of NVCs decreased although the number of NVCs did not change. Regarding the unchanged number of NVCs following the urethane-anesthesia, it is conceivable that the further reduced response could not be detected after urethane because this value has been already reduced after RTX treatment although the value tended to decrease. Since urethane-anesthesia itself did not show any cystometric changes in vehicle-treated rats, urethane-anesthesia has a potentially synergistic suppressive effect on RTX induced desensitization in SCI rats.

In the clinical investigation in the patients with SCI, intravesical CAP or RTX induced the increase in bladder capacity and the decrease in DO as well as voiding detrusor contractions.^{3–8} These reports are consistent with our findings in SCI rats under a conscious condition. However, the effects of desensitization are enhanced if this investigation is performed under urethane-anesthesia, and this may not reflect the clinical observations. Thus, at least in rats with SCI, pharmacological studies may need to carry out without urethane-anesthesia to evaluate drug-effects appropriately.

CONCLUSIONS

The present results indicate that the suppressive effect of RTX on non-voiding contractions as well as voiding contractions in SCI rats can be enhanced by urethane-anesthesia. Such suppressive effect of urethane-anesthesia itself should be taken into consideration when we evaluate a drug-effect on LUT function in rats with SCI.

ACKNOWLEDGMENT

The present study has been supported by a Grant-in-Aid for Scientific Research (YI; Grant no. 40159588, NA; Grant no. 80595257), from the Ministry of Education, Culture, Sport, Science and Technology of the Japanese Government.

REFERENCES

- de Groat WC. Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury. *Paraplegia* 1995;33:493–505.
- Brady CM, Apostolidis AN, Harper M, et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. *BJU Int* 2004;93:770–6.
- de Seze M, Wiart L, Joseph PA, et al. Capsaicin and neurogenic detrusor hyperreflexia: A double-blind placebo-controlled study in 20 patients with spinal cord lesions. *NeuroUrol Urodyn* 1998;17:513–23.
- de Seze M, Wiart L, de Seze MP, et al. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: A double-blind, randomized, controlled study. *J Urol* 2004;171:251–5.
- Cruz F, Guimaraes M, Silva C, et al. Suppression of bladder hyperreflexia by intravesical resiniferatoxin. *Lancet* 1997;350:640–1.
- Cruz F, Guimaraes M, Silva C, et al. Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. *J Urol* 1997;157:585–9.
- Fowler CJ, Beck RO, Gerrard S, et al. Intravesical capsaicin for treatment of detrusor hyperreflexia. *J Neurol Neurosurg Psychiatry* 1994;57:169–73.
- De Ridder D, Chandiramani V, Dasgupta P, et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: A dual center study with long-term followup. *J Urol* 1997;158:2087–92.
- Cheng CL, de Groat WC. The role of capsaicin-sensitive afferent fibers in the lower urinary tract dysfunction induced by chronic spinal cord injury in rats. *Exp Neurol* 2004;187:445–54.
- Cheng CL, Ma CP, de Groat WC. Effect of capsaicin on micturition and associated reflexes in chronic spinal rats. *Brain Res* 1995;678:40–8.
- Matsuura S, Downie JW. Effect of anesthetics on reflex micturition in the chronic cannula-implanted rat. *NeuroUrol Urodyn* 2000;19:87–99.
- Hara K, Harris RA. The anesthetic mechanism of urethane: The effects on neurotransmitter-gated ion channels. *Anesth Analg* 2002;94:313–8, table of contents.